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DNA-anti-DNA immune complexes are thought to play a major role in the pathogen- 
esis of tissue injury in systemic lupus erythematosus (SLE)  1 (1, 2). Involved kidneys and 
skin contained deposits of extranuclear single-stranded DNA (ssDNA),  double-stranded 
DNA (dsDNA) and antibodies to DNA (1,  3-5).  The presence of antibodies to DNA in 
circulation was not sufficient to induce disease  (6-8),  leading several investigators to 
propose that DNA antigen must be present in the circulation or deposited in tissues to 
form immune complexes  (2,  6,  9).  Sera of some SLE patients  contained  significantly 
higher  levels  of ssDNA  and  dsDNA than  did  normal  controls  (2,  9-11),  and  serial 
studies  on some of these  patients  (2,  9)  indicated that serum  DNA antigen and anti- 
DNA  antibody  levels  may  alternate,  suggesting  possible  intermittent  formation  of 
immune complexes in the circulation. Tan (12) and Gabrielsen (13) postulated that DNA 
is normally released into the circulation with cell breakdown in skin and bone marrow, 
or with tissue injury. 
The in vivo behavior and breakdown of DNA was first studied by LeDoux (14) and 
others  (15, 16) with reference to the potential transforming ability of exogenous viral 
DNA. They found that DNA was rapidly degraded and that its transforming ability was 
destroyed  in  vivo within  several  minutes.  Tsumita  and  Iwanaga  (17) reported  that 
>90%  of administered  calf thymus  DNA was  removed from the  circulation of mice 
within 30 rain,  and that the  major organ of uptake was the liver.  Chused et al.  (16) 
confirmed the  rapid  clearance  (90% at  20  min)  for both  single-stranded  and  double- 
stranded KB-cell DNA and they showed that early clearance was faster in older NZB/W 
mice  with  antibodies to  DNA than  in younger mice without detectable  antibodies to 
DNA.  Furthermore,  DNA appeared  to  be  removed as  an  intact  macromolecule, and 
reticuloendothelial  uptake was thought to be the  mechanism responsible.  Natali  and 
Tan (19), using native calf thymus DNA in rabbits,  and Dorsch et al.  (20) and Chia et 
al.  (21), using denatured calf thymus DNA in  mice,  confirmed the rapid clearance of 
DNA from circulation. 
This rapid clearance of DNA in experimental animals appears inconsistent with the 
finding of high levels (up to 200 pg/ml) of circulating DNA in patients with SLE (9). 
This  would  suggest  that  under  some  conditions,  the  DNA  removal  mechanism  is 
altered, that the DNA itself is different, or that large amounts of DNA are released into 
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circulation.  Previous clearance studies  in animals  (18-20) employed only one or several 
low doses of DNA, well below the measured concentrations  in SLE patients. 
For these  reasons,  ssDNA  clearance  kinetics  were  examined  using  a  variety 
of  doses  of  a  defined  preparation.  The  data  indicate  that  ssDNA  clearance 
mechanisms  are saturable  at relatively  low doses of ssDNA,  and  that  a  hepatic 
membrane-bound  enzyme,  as well as circulating  endonucleases,  contributes  to 
the  removal  and  degradation  of circulating  ssDNA. 
Materials  and Methods 
Preparation  and lodination ofDNA.  Calf thymus DNA (Lot 36E672; Worthington Biochemical 
Corp.,  Freehold,  N.  J.) was  dissolved to a  concentration of 1 mg/ml in  0.003  M  NaC1,  passed 
through an HAWP 2500 Millipore filter (Millipore Corp., Bedford, Mass.), and stored at 4°C. 5-ml 
aliquots were denatured  by placing them in a  boiling water bath for 60 min, followed by rapid 
cooling on ice. This heat-denatured  DNA solution was mixed with hydroxyapatite  (DNA-grade 
Bio-Gel HTP; Bio-Rad Laboratories,  Richmond,  Calif.) at  1 mg DNA/g of hydroxyapatite  and 
washed serially with 0.06 M, 0.16  M, and 0.48 M sodium phosphate buffer at pH 6.8, according to 
the method of Paetkau  and Langman  (22).  The DNA recovered with 0.16  M sodium phosphate 
was considered ssDNA  (23). To assess  the amount of contamination with dsDNA, Neurospora 
crassa  single-stranded endonuclease (Miles Laboratories Inc., Elkhart, Ind.) was added at 30 U/ 
/~g,  and  the  mixture  was  incubated  for  60  rain  at  37°C.  91%  of the  DNA was  hydrolyzed  to 
trichloroacetic  acid  (TCA)-soluble products,  indicating  <10%  double-stranded  material  in  the 
ssDNA preparation,  ssDNA was filtered over Sepharose 4B columns (Pharmacia Fine Chemicals, 
Piscataway,  N. J.) in 0.2 M sodium borate and 0.15 M NaCl at pH 8.0.  The elution pattern was 
recorded by absorbance at 260 nm and it revealed a  large excluded peak representing 40-50% of 
the initial preparation,  as well as a broader included peak.  In an attempt to obtain a  relatively 
large molecular weight, but a  homogenous preparation,  the fractions in the ascending portion 
and peak  of  the  included curve were pooled (designated as  ssDNA Pool II),  characterized,  and used 
in subsequent animal studies. 
When iodinatod  ssDNA was needed, the ssDNA eluted  from hydroxyapatite with 0.16  M sodium 
phosphate was labeled  with 125I,  according to the method of  Commerford (24).  Adequate labeling 
was obtained, with specific activities  in the range of 5 x  104-105 cpm/~g.  ARer extensive 
dialyses  to remove free  1251,  preparations were subjected  to  gel filtration,  as described above. The 
elution  pattern was found to be the same as that of  unlabeled DNA, and the same fractions  from 
the included peak were pooled (1251-ssDNA Pool H) for use in animal experiments. 
To insure that the  1251  had been incorporated into DNA  rather than into contaminating 
protein  or RNA, the 1251-ssDNA was incubated with 100 ~g protease/~g DNA  (Protease Type VII, 
Sigma Chemical Co.,  St.  Louis, Mo.) or  with 100 ~g  RNAse/~g DNA  (RNAse I, Miles Laboratories 
Inc.), at 37°C for 24 h, and the amount of ~2SI-labeled  soluble in 10% TCA  was determined to 
indicate the presence of labeled amino acids or ribonucleotides. Before enzyme treatment, 1.5- 
2.0% of  the x25I-ssDNA was soluble,  and was believed to represent free  12sI  or 125I-deoxycytidine 
contamination.  Treatment with protease failed  to release any additional soluble label.  RNAse 
treatment increased the soluble products from 2 to 3%. We therefore concluded that the ~25I- 
ssDNA preparations were contaminated with ---1%  RNA, and no measurable protein.  Treatment 
with protease and/or RNAse was therefore not performed on the preparations used in animal 
experiments. 
Determination  of DNA  Size.  Electrophoresis  of ssDNA  samples  was  performed in  a  3.5% 
polyacrylamide gel, according to the method of Maniatis et al. (25), using bromophenol blue and 
xylene cyanol as markers.  Electrophoresis was performed on a  9 ×  9-cm gel slab, 2-3 mm thick, 
at a voltage of 15 V/cm for 2-3 h.  Gels were cut into 3-ram slices, counted for radioactivity, and 
the distance migrated for each peak was expressed as a fraction of the bromophenol blue migration. 
Using the standard curves of Maniatis et al., obtained with&X 174 ssDNA fragments (25), the mean 
size of the ssDNA (Pool II) was estimated to be 450 nucleotides, with less than 5% smaller than 100 or 
greater  than  1,000  nucleotides.  Plasma  samples,  obtained  in  heparin-coated  micropipettes  at 
varying intervals after injection of radiolabeled ssDNA preparation,  were diluted to 80  ~l with 686  REMOVAL  OF  CIRCULATING  SINGLE-STRANDED  DNA  IN  MICE 
0.01  M  phosphate-buffered saline  (PBS) at  pH 7.2 and then examined under the same conditions 
of  electrophoresis. 
Animal Experiments.  Female 3- to 4-too-old  C57Bl/6J mice (18-22  g) were given potassium 
iodide  in their  drinking  water at least  12 h before  experiments. Pool II  ssDNA and Pool II I~sI- 
ssDNA  were combined to obtain the desired dose and radioactivity  for injection.  Control 
experiments in which the clearance kinetics  of labeled DNA  were compared to the clearance 
kinetics  of  a mixture of  labeled  and unlabeled DNA  revealed  no differences  in in  vivo  behavior of 
the two preparations. 
Varying doses of  ssDNA (2, 10, 50, 100,  and 500 pg) in a 0.5-mi  volume of  borate buffer  were 
injected  into  the tail  vein,  and 20-~i  blood samples were obtained from the retro-orbital  venous 
plexus at 30 s, 1, 2, 3, 5, 10, 20, 30, and 40 rain,  and 1, 2, 4, and 8 h. Blood samples were 
immediately washed from the micropipettes  with 0.75  ml of  borate buffer  into  0.25  ml of  carrier 
DNA  solution  containing 250 fig of  unlabeled DNA, and 1.0 ml cold  10% TCA was added. The 
samples were centrifuged at 2,500  g for 20 rain  at 4°C,  the supernate was removed, and the 
precipitate  and supernate were counted in an automatic, well-type gamma  counter (Searle 
Diagnostics Inc.,  DesPlaines, Ill.).  In some animals, 100 ~I of  blood was drawn into  heparin- 
coated micropipottes at 1, 5, and 10 rain  and then centrifuged.  50 pl of plasma was used for 
electrophoresis  as described  above, to  estimate the size  of  the DNA  remaining in circulation. 
1 rain  before  sacrifice,  some animals were injected  with 0.1 ml of  rabbit  IgG, iodinated  with 
13'I  as a plasma volume marker. These animals  were killed  by exsanguination through  the renal 
artery and the organs,  blood,  and carcasses  were counted for calculation  of  organ uptake (see 
below). 
Serum and urine were obtained from  some animals  30 rain  aRer injection.  These samples  were 
loaded onto a DEAE  Sephadex A-25  column (Pharmacia  Fine Chemicals) at  4°C,  and  equilibrated 
with 0.01 M  Tris  HCI at pH 7.2.  The column was washed with 50-60 ml of  starting  buffer  and 
then linear  gradient elution  was performed up to 1 M  NaCl. Calibration  using carrier  free  1251 
(New England Nuclear, Boston, Mass.) and iododeoxycytidine (Sigma Chemical Co.)  showed 
that the iododeoxycytidine  eluted  in the wash, and 125I  was eluted  at 0.6-0.7  M  NaCI. 
In Vitro Nuclease Assay 
EX0NVCL~.ASE.  Blood, obtained from noninjected animals by cardiac puncture, was immedi- 
ately spun in a chilled, siliconized tube, and the plasma was removed, ssDNA was added to fresh 
plasma, whole blood, or PBS at the concentration attained in vivo for a mouse receiving a  100-/~g 
dose of  ssDNA. This  was  calculated  to  be 1 fig  ssDNA/20/~I of  blood  or  I ~g ssDNA/10 ~I  plasma, 
assuming a blood volume of  2 ml and a hematocrit of  50. Each sample was incubated at  37°C for 
10 rain  in the presence of 0.01 M  MgSO4. In a parallel  experiment performed to check for 
nuclease inhibitors,  blood,  plasma, or  buffer  was incubated with 1 ~tg  ssDNA in the presence of 
70 pg DNAse II (Sigma Chemical Co.)  and MgSO4. After incubation,  250 ~g of  cold  carrier  DNA 
and 1.0 ml of 10% TCA was added, samples were centrifuged for 20 rain  at 2,500  g, and the 
precipitate  and supernate were counted. Results were expressed as the percentage of  counts in 
the soluble  fraction  over the total  counts.  Each sample contained 50,000-60,000  cpm to minimize 
counting error. 
ENDONUCLEASE.  TO assess  the in  vitro  effect  of  plasma  on degradation of  precipitable  ssDNA, 
plasma obtained from noninjected  animals was mixed with the starting  ssDNA preparation and 
incubated at  37°C for  1, 10, and 30 rain.  The reaction  was arrested  by cooling  on ice,  and the size 
of  the ssDNA was determined by polyacrylamide gel  electrophoresis  as described  above. 
Analysis  of  Data.  Immediately  before  each  experiment, a sample of  the ssDNA to  be injected 
was counted and a specific  activity  in cpm/~g was determined. Using this  specific  activity, 
counts remaining in the 10% TCA  precipitate,  supernate, and whole blood (precipitate  plus 
supernate) were converted to ~g of  DNA  remaining/ml, and the concentration  versus time data 
were plotted  on semilogarithmic paper.  Clearance velocities  were calculated  using the formula: 
V = 2.3026  K So, where So  and K are the y-intercept  and slope,  respectively,  of  the line  obtained 
by linear regression analysis of the early data points as presented under Results. Since the 
clearance kinetics  were nonlinear functions,  curve analysis  was also  carried  out using the PDP- 
10 MLAB  program (26)  for  a nonlinear regression  analysis  (Division  of  Computer Research and 
Technology, National Institutes  of Health, Bethesda, Md.).  Least squares test  fits  were deter- 
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velocity (V  m) and Michaelis-Menten constant (Km) were obtained, and clearance curves were 
simulated using  these parameter estimates. 
Production velocity  of  TCA-soluble label  was analyzed  according  to  the formula: V = 2.3026  K 
So, where K  and So were the slope  and y-intercept  of  the line  derived from linear  regression 
analysis  of  the first  seven data points.  This extrapolated So for soluble  material was found to 
closely approximate the number of micrograms of soluble label in the initial  preinjected 
preparation (1-1.5% of  injected  dose). 
Specific  organ uptake was determined by calculating  I~II  and ~25I  counts per minute for each 
organ, and for 100 ~tl of blood at the time of sacrifice.  The 13~I  counts per minute per organ 
divided by the ~31I  counts per minute per milliliter  of  blood yielded  the total  milliliters  of  blood 
per organ. When both isotopes  were present in a specimen, the 1251  counts were corrected  for  the 
Compton scatter  of  ~3~I.  Specific  organ uptake was calculated  as follows: 
U  ~  "  [  125I cpm\  [  13'I cpm/organ  ~  x 
specific  pzaze  = ~ or-~nn )  -  \  '3'I cpm/ml of bloo  v  leI cpm/ml of blood. 
Since  the  specific  activity  of the  DNA  was  known,  the  pg  DNA  uptake  per  organ  could  be 
calculated  (27). 
Results 
Disappearance Kinetics  of Injected  DNA.  The  whole blood disappearance 
curve  of  a  2-~g  dose  of  125I-ssDNA  (Figure  1A)  showed  an  initial  rapid 
exponential phase during which 90% of the administered dose was removed. A 
second,  slower component  was  also evident  with  an  increase  in  whole blood 
radioactivity at 30 min.  This late increase in radioactivity was observed with 
all administered doses of ssDNA. Since it was thought that this late component 
might be a result of the production of breakdown products, whole blood samples 
were  precipitated  with  10%  TCA,  and  the  soluble  (mononucleotide  or  free 
iodine) and precipitable (polynucleotide) fractions were analyzed separately. In 
this way, most breakdown products were excluded from analysis of disappear- 
ance  curves.  The  clearance  curves of the  TCA-precipitable  ssDNA showed a 
rapid initial clearance phase without a late increase in whole blood radioactiv- 
ity. A second, slow or exponential component, representing  1.5-2% of the total 
injected material,  was present in the TCA-precipitable DNA curves. Attempts 
to isolate and to characterize this persistent precipitable DNA by gel filtration 
and acrylamide electrophoresis showed that it was <1,000 daltons mol wt, and 
was  not  protein  bound.  Furthermore,  when  free  125I, a  known  TCA-soluble 
material,  was added  to whole blood and  precipitated  with  10%  TCA,  as was 
done routinely in animal  experiments,  8-10%  of the  label became trapped  in 
the precipitate.  Therefore, the TCA-precipitable DNA curves were analyzed by 
subtracting  10%  of the  soluble counts  at  a  given  time  from the  precipitable 
counts at that same time to correct for the counts entrapped in the precipitate. 
Analysis of the disappearance curves in this manner  almost completely elimi- 
nated  the  slow  component  and  showed  the  disappearance  curves  of TCA- 
precipitable ssDNA to be a  rapid,  exponential function (Fig.  1 B). 
Effect of Varying Dosage on Disappearance Kinetics.  The clearance kinetics 
of TCA-precipitable ssDNA were examined aiter the administration  of 2,  10, 50, 
100, and 500 p~g of ssDNA. As shown in Fig. 2, the rate of ssDNA clearance was 
not linearly related to dose, but clearance became saturated with increasing doses 
of ssDNA. In addition, the clearance velocity for any given dose was not constant, 688  REMOVAL  OF  CIRCULATING  SINGLE-STRANDED  DNA  IN  MICE 
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FIG. I.  Disappearance curves of ssDNA from circulation  of mice. (A),  the remaining 
whole blood radioactivity  after  administration of  2 /~g  ssDNA was converted to ~g DNA/ 
ml by the formula: DNA  ~g/ml = cpm per 20/~l  sample x 50/cpm per ~g DNA. Each data 
point  represents  the mean +- SD of  at least  five  mice.  An initial  rapid phase of  disappear- 
ance from blood is present,  and then the amount of DNA  remaining increases.  (B),  the 
amount of  ssDNA precipitable  with 10% TCA remaining in circulation  is plotted  for the 
same mice as  in (A).  The blood  disappearance of  TCA-precipitable ssDNA is  described  by a 
single  rapid exponential function. 
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FIG.  2.  Observed  data  points  and  computer-simulated precipitable  ssDNA  clearance 
curves based on estimated parameters (Vm and K m) for each administered dose.  Each (0) 
represents the mean observed value at each measured time point. The applicability of the 
Michaelis-Menten  model to the data is evident from the close agreement of curves. WOODRUFF  EMLEN  AND  MART  MANNIK  689 
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FIG.  3.  Clearance kinetics ofTCA-precipitable ssDNA. Clearance velocities (~g/ml/rnin) 
were calculated using linear regression analysis of early data points (see text), and they 
reach a  maximum with higher doses. 
but changed with the concentration of  ssDNA in circulation  at any given time 
as reflected  by the changing slopes of the curves, particularly with higher 
doses. This behavior was consistent with a saturable, Michaelis-Menten clear- 
ance mechanism (28,  29, 30).  Accordingly, clearance velocities  were calculated 
using data from 30 s to 5 min for the 2,  10, and 50 ~g doses, and from 30 s to 10 
rain  for  the  higher  doses  (Materials  and  Methods).  A  dose-versus-clearance 
velocity curve yielded an approximate Vm of 6 ~g/ml/min and a  Km of 35 ~g/ml 
(Fig.  3).  However,  since  clearance  velocity for any given  dose changed  with 
time, as illustrated in Fig. 2, considerably different velocities could be generated 
for each dose by including  more or fewer data points in the linear regression 
analysis.  Therefore, the data were fit to the Michaelis-Menten equation (dC/dt 
=  -VmC/(Km  +  C), where C  -- concentration,  and t  =  time) by the method of 
least squares by the MLAB computer program and V m and K m were generated 
for each dose.  Using these parameter  estimates,  the computer  simulated  the 
clearance  curves which were described by the  Michaelis-Menten  equation.  A 
high  degree of agreement  of the  data with the  Michaelis-Menten  model was 
found, as indicated in Fig. 2 by the close superposition of observed data points 
and  the  curves  predicted  by the  model.  No  systematic  deviations  from  the 
model were apparent at either end of the curves. 
Organ Uptake of Injected DNA.  Specific organ uptake in the liver, spleen, 
kidneys,  lung,  and  skin  was  studied  at  3,  20,  and  60  rain.  As  reported 
previously (17,  18,  20),  the  liver was by far the  major organ  of uptake,  with 
94.5%  of the  2  ~g-dose present in the liver at 20 rain,  and  8%  at 60  min.  At 
higher  doses,  however,  the  amount  of radioactivity  in  the  liver  remained 
constant or actually increased over time. The larger the dose of ssDNA injected, 
the longer the liver continued to accumulate the radiolabeled material.  This 
accumulation  of radioactivity  over time  suggested  to  us  either  re-uptake  of 
breakdown  products  or  storage  of  material.  To  determine  the  role  of the 
various organs  in removal kinetics,  organ  uptake was examined  at 3 rain,  a 
time when minimal reuptake of storage of radioactivity can be assumed. Fig. 4 
shows the hepatic uptake curve and the removal of ssDNA from blood at 3 rain 
at different doses. The liver accounted for ~ 90% of DNA removal at 3 min at 
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FIG.  4.  Specific liver uptake  (-)  of ssDNA in mice sacrificed 3  min after injection of 
DNA. Each point represents the mean _+  SD for 3-4 mice. (  ....  ) represents the amount 
of precipitable ssDNA removed from circulation in the first 3 min after injection, based on 
the curves shown in Fig. 2. Hepatic uptake accounts for ~-90% of the ssDNA removed from 
circulation at all doses. 
Renal  uptake represented  only 2-5% of the total  ssDNA removed from the 
circulation,  and did not increase with increasing the dose. Whether this renal 
uptake  represents  only soluble breakdown products  in  the  tubules  or larger 
DNA at other sites within the kidney is currently under investigation.  Splenic 
uptake  played  only  a  small  role  in  ssDNA  removal.  However,  as  the  liver 
became  saturated  with  higher  doses  of DNA,  splenic  uptake  appeared  to 
increase from 2.2% of the  DNA removed with a  2-/~g dose to 7% of the  DNA 
removed with a  500-ftg dose. Lung and skin tissues showed negligible (<1% of 
the removed DNA) uptake at all examined time points (3, 20,  60 min). 
Appearance of TCA-Soluble  Material.  The appearance of TCA-soluble ma- 
terial  in the circulation  was studied.  Immediate production of soluble break- 
down  products  was  observed with  no  lag  phase  (Fig.  5).  Significantly  more 
TCA-soluble  material  was  present  in  the  circulation  at  2  min  than  in  the 
starting  preparation  (1-2%  of starting  preparation  was  soluble).  Production 
increased to a peak at 30-40 min and then declined gradually.  For comparison, 
the  generation  of TCA-soluble  breakdown  products  was  also examined  with 
immune  complexes  consisting  of human  serum  albumin  and  antibodies  to 
human serum albumin,  material  known to be cleared from circulation by the 
hepatic  mononuclear  phagocyte  system  (Kupffer  cells)  (27).  These  curves 
showed a  40-60  min lag before any increase was demonstrable  in circulating 
soluble products. 
The  velocity  of production  of TCA-soluble  material  at  different  doses  of 
ssDNA was calculated usingdata  points from 30 s  to  10 min.  A  plot of dose- 
versus-production velocity showed that the velocity approached a  maximum of 
0.2  ~g/ml/min  with  a  K m of  130. These  values  are  obviously  inaccurate, 
however, since they will be greatly affected by cellular reuptake  and urinary 
excretion  of breakdown  products.  Indeed,  urinary  excretion  of  breakdown 
products, although not quantitated,  was rapid.  Radioactivity was detectable in 
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FIG. 5.  Amount of  TCA-soluble ssDNA present in the circulation  after  administration of 
50/~g of  ssDNA. Each point represents the mean -+ SD of  at least  five  mice. ~g of  soluble 
ssDNA/ml were calculated  using the specific  activity  in  cpm/~g of  the injected  preparation 
(as  in Fig. 1). Immediate production of  breakdown products is  evident without a lag phase. 
To  demonstrate  that  the  above  measured  soluble  radioactivity  actually 
represented  ssDNA  breakdown  products,  serum  and  urine  obtained  30  min 
after  injection  were  passed  over  ion  exchange  columns.  50-60%  of  serum 
radioactivity was shown to be iododeoxycytidine and the remainder  was free 
iodine  or  dinucleotides.  Only  30%  of  the  125I label  in  the  urine  could  be 
identified as iododeoxycytidine; most of the urinary soluble products were free 
1251. 
Serum  Nuclease Activity.  To  examine  if the  rapid  appearance  of soluble 
products  was  the  result  of a  circulating  plasma  factor,  fresh  plasma  was 
assayed in vitro for exonuclease activity,  ssDNA was added to plasma at the 
same concentration  as  was  present  in  vivo in  mice receiving  a  100-ftg dose. 
Table  I  shows that  no  plasma  exonuclease  activity was  demonstrable  at  10 
rain,  a time at which significant breakdown of ssDNA was evident in vivo. The 
activity of a commercial DNAse was not inhibited by the addition of even large 
amounts of plasma,  indicating that no exonuclease inhibitors were present in 
plasma which might have blocked ssDNA breakdown in the in vitro assay. 
Characterization  of Precipitable DNA Remaining  in Circulation.  In addi- 
tion to the cleavage of soluble products from the DNA molecule by exonucleases, 
large precipitable DNA is cleaved into smaller fragments by endonucleases. To 
characterize the size of circulating ssDNA, plasma obtained at 1, 5, and 10 rain 
after  injection  of 20  ~g  of ssDNA was  characterized  by electrophoresis  on  a 
3.5% polyacrylamide gel. A rapid decrease in size of the DNA occurred (Fig. 6), 
with a reduction to approximately one-half of the starting molecular weight of 
the DNA at i  min.  At 10 rain,  the ssDNA remaining in circulation was cleaved 
to 80-120 nucleotide  fragments  (25,000-35,000  tool wt),  roughly  one-sixth  the 
size  of the  injected preparation.  The  l-rain  sample  and  controls  with ssDNA 692  REMOVAL  OF  CIRCULATING  SINGLE-STRANDED  DNA  IN  MICE 
TABLE  I 
The Generation of TCA-Soluble ssDNA Products by Whole Blood, Plasma, and DNAse 
In Vitro 
Digestion mixture* 
No DNAse added  DNAse added~l 
Soluble radioactiv- 
n$  n  Soluble radioactivity 
ity§ 
%  % 
ssDNA +  PBS  8  2.63  _  0.96¶  5  69.53  -+  1.72 
ssDNA +  blood  12  1.87  -+ 0.29  7  71.31  _  1.74 
ssDNA +  plasma  10  2.20  -+ 0.45  5  72.28  +_ 0.83 
* I  ~zg Pool II ssDNA added to 20 ~1 0.01 M  PBS pH 7.2, 20 ~1 whole blood, or 10/~l fresh plasma, 
and incubated with 0.01 M  MgSO4 at 37°C for 10 min. 250 ~g carrier DNA was added and the 
mixture was precipitated with cold 10% TCA. 
$ n, number of samples tested. Each sample was done in duplicate, and no more than two blood or 
plasma samples were obtained from any individual mouse. 
§ Percent  radioactivity  equals  cpm  supernate/cpm  precipitate  +  cpm  supernate,  expressed  as 
the mean  +__  1 SD. 
II  Commercial DNAse added as a  positive control (see text). 
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FIG.  6.  Migration of radiolabeled ssDNA  on polyacrylamide  gel electrophoresis.  (A) 
indicates  the radioactivity  in 50 ~I of plasma obtained at 1 rain,  and (m),  in 50 ~l of 
plasma  obtained 5 min after  injection  of  20/~g  of  ssDNA. (0)  represents  the  electrophoresis 
pattern of  a mixture in vitro  of  0.5 pg ssDNA and 50 ~l normal plasma. Assuming a 2-ml 
blood  volume for  a 20-g  mouse, this  represents  the  theoretical  concentrations  of  ssDNA in 
plasma at time 0. Electrophoresis  was performed on 3.5% polyacrylamide slabs  in 0.09  M 
Tris  borate,  2.5 M  EDTA  buffer  pH 8.2 at 10 V/cm for  2 h. 3-mm slices  were cut,  counted 
for ~25I  radioactivity,  and plotted  as distance migrated from the well.  Bromophenol blue 
and xylene cyanol migrated  6.2  and 3.1  cm, respectively,  under  these conditions,  and were 
used for  approximate molecular weight calculations  (25)  (Table II). 
added to fresh plasma showed a large amount of material remaining near the 
well, suggesting possible interaction of DNA with serum proteins. It is of note 
that at later times, as the DNA was broken down to smaller sizes, less protein 
binding occurred. Analysis of the amount of ssDNA remaining in different size 
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TABLE II 
Size of Precipitable ssDNA Remaining in Circulation 
Time after 
injection 
Size  of DNA(nucleotides)* 
>500  250-500  100-250  <100 
min  J~g 
05  11.26  _+  1.70§  5.83  +- 0.69  2.34  _+ 0.88  0.56  -+ 0.17 
1  4.80  -+ 0.15  4.99  -+ 0.01  4.68  -+ 0.42  1.93  -+ 0.64 
5  0.38 -+ 0.05  0.93  -+ 0.01  4.52  _+ 0.15  3.25  _+  1.30 
10  0.25  _+  0.01  0.48  _+ 0.09  0.85  -+ 0.25  1.62  _+ 0.58 
* Based on PAGE of samples using the standard curves of Maniatis et al.  (25) for ¢b X174 ssDNA. 
ssDNA mixed with  fresh  plasma  in  vitro  and  immediately  subjected  to  polyacrylamide  gel 
electrophoresis. 
§ Mean (#ag)  _+  1 SD based on two experiments, after administration of 20 ~g of ssDNA. 
time (Table II), indicating cleavage of ssDNA rather than the mere selective 
removal of larger molecules. 
To  determine  if this  rapid  cleavage  could  be  attributed  to  a  circulating 
enzyme, ssDNA was incubated with fresh plasma without anticoagulants, or 
with heparinized plasma at 37°C for 30  rain. Electrophoresis of these samples 
showed a  definite decrease in size of the ssDNA after incubation with either 
heparinized or unanticoagulated plasma.  Data were insufficient to  allow for 
accurate quantitative comparisons with in vivo breakdown.  However,  it ap- 
peared  that some,  but  not all of the endonuclease activity observed in vivo 
could be attributed to circulating enzymes. 
Discussion 
Previous  studies  have  shown  that  administered DNA  is  rapidly removed 
from the circulation by the  liver,  and phagocytosis by the Kupffer cells was 
suggested  as  the  mechanism  responsible  for  this.  Because  of  the  known 
saturability of  the mononuclear phagocyte system with a number of substances, 
it seemed pertinent to examine whether or not this held true for DNA as well. 
This  study has  therefore  attempted to  define the  behavior  and  clearance 
mechanisms of exogenously administered ssDNA over a  wide range of doses. 
The work of Chused et al.  (18), Dorsch et al.  (20) and Tsumita and Iwanaga 
(17)  was  confirmed by  showing that  ssDNA  was  rapidly removed from the 
circulation  and  that  the  major  organ  of removal  was  the  liver.  When  the 
clearance of total radioactivity was followed over time (Fig.  1 A), there was a 
late rise in circulating label at 30-40  min. This increase was the result of the 
appearance of TCA-soluble breakdown products in the circulation, and a large 
portion of those breakdown products could be identified as iododeoxycytidine, a 
mononucleotide. Breakdown products were  rapidly excreted in the  urine  as 
either free 12~I or 125I-deoxycytidine. 
When  these  breakdown  products  were  excluded from curve  analysis,  the 
clearance mechanism for ssDNA was clearly saturable (Figs. 2 and 3) and the 
kinetics closely fit a  Michaelis-Menten clearance model. This model, although 
originally  described  for  simple  enzyme  systems,  has  been  applied  to  the 
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diphenylhydantoin  (30) and ethanol (31) by Sedman et al. Computer-simulated 
curves  based  on  this  model  (29,  30)  for other  substances  looked remarkably 
similar  to the whole blood disappearance  curves for ssDNA shown in  Fig.  2. 
We therefore applied our data to the Michaelis-Menten equation and obtained 
a high degree of agreement (Fig. 2). The mean values of the computer estimates 
for V m and Km were 7.2  _+  1.4 ~g/ml/min  and 36.5  _+  14.0  ~g/ml,  respectively. 
These values agreed quite well with the V~ of 6.0 ~g/ml/min and Km of 35 ~g/ 
ml, determined by simple dose-versus-clearance velocity graphing  (Fig. 3). The 
usual concept of half life is not valid in describing nonlinear data such as this, 
since the rate  of clearance  is constantly  changing  over time  (32).  To further 
describe this system, we chose to measure the time taken for removal of 90% of 
the  administered  dose.  At  low doses such  as the  2-~g dose used in  previous 
studies (18, 20), 90% of the administered dose was removed at 3 min.  However, 
since the removal mechanism was saturable,  precipitable ssDNA persisted in 
the circulation considerably longer at higher doses. Removal of 90% of the 100- 
~g dose took 20 min,  and removal of the 500-~g dose took 41 min. 
The  organ  uptake data  confirmed previous work (17,  18,  20),  showing that 
the liver was the major organ for removal of circulating ssDNA. Furthermore, 
liver  uptake  was  saturable  in  parallel  with  whole  blood clearance  (Fig.  4), 
suggesting that precipitable ssDNA clearance was mediated by binding to liver 
cells, and that as liver uptake mechanisms became saturated, clearance became 
saturated.  Renal uptake represented 2-5% of the removal mechanism  and did 
not alter with the alteration of the dose administered.  Splenic uptake, however, 
increased in relative  importance  as the liver became saturated,  suggesting a 
possible  overflow  or  safety-valve  role  for  the  spleen  in  clearance,  even  if 
relatively small in comparison to hepatic uptake. 
The  possible role of antibodies  to  ssDNA must  be considered  in  the  rapid 
hepatic uptake of this material, since Thoburn et al. (32a) demonstrated that 44% 
of 7- to 12-mo-old C57B1/6J mice had endogenous antibodies to ssDNA.  Poten- 
tially, exogenous ssDNA could combine with antibodies and be removed by the 
mononuclear phagocyte system as large lattice immune complexes.  However, 
the removal of ssDNA occurred 25-30 times faster than the removal of an equal 
dose of preformed  immune  complexes  (27).  Furthermore,  as discussed below, 
phagocytosis of immune complexes is characterized by a lag in the appearance 
of breakdown products in the circulation,  a  phenomenon which was not seen 
with  ssDNA.  Finally,  when  ssDNA binding  was  measured  by Farr  assay in 
sera of eleven 3- to 4-mo-old C57B1/6J mice, we found no antibodies to ssDNA. 
Therefore, we conclude that the clearance of ssDNA described in this study is 
not  dependent  upon  immune  complex  formation,  but  is  a  function  of the 
ssDNA itself. 
The saturability of organ uptake and of clearance of ssDNA may be relevant 
to the finding of high levels of circulating ssDNA in patients after hemodialysis 
of trauma,  or in those with SLE.  Potentially,  if a  large bolus of ssDNA were 
released into the circulation, such as might occur after tissue injury or sunburn, 
clearance mechanisms could become saturated, enabling large molecular weight 
ssDNA  to  persist  in  circulation.  Moreover,  if the  removal  mechanism  was 
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ssDNA might also remain in circulation longer than normal. Increased amounts 
of ssDNA  might then be  available for combination with  antibodies to  form 
immune  complexes,  for  local  deposition  in  tissues,  or  for  presentation  to 
immunocompetent cells. It is important to note that we could find no increased 
renal deposition of ssDNA at high doses, but that splenic uptake did increase 
slightly. To discover whether or not this splenic uptake is important in terms 
of increased  antigen  presentation  to  immunocompetent cells  would  be  an 
intriguing study. However, the localization and molecular weight of the DNA 
within organs must be defined before any conclusions can be drawn. 
This study also enabled us to make some statements about ssDNA degrada- 
tion in  vivo  and the  size  of ssDNA  which persisted  in  circulation.  DNA  is 
broken down in biological systems by two groups of enzymes; exonucleases and 
endonucleases  (33). Exonucleases  attack  the  ends  of polynucleotide chains, 
yielding mononucleotides which are soluble in 10% TCA. Endonucleases attack 
linkages within the polynucleotide chain yielding shorter fragments, but they 
cannot degrade these fragments to soluble (mononucleotide) residues.  One or 
both of these enzymes could potentially act: (a)  intracellularly, aider phagocy- 
tosis or membrane transport of the ssDNA molecule into a  cell, (b) within the 
circulation, or (c) at the cell surface (membrane-bound enzyme). 
Exonuclease activity was  measured by the appearance of TCA-soluble 125I 
label in the circulation. If exonucleases were intracellular and required prior 
phagocytosis of ssDNA,  one  would  expect  a  lag phase  of at  least  6-30  rain 
before the appearance of breakdown products in the circulation. This has been 
shown by Palmer et al.  (34, 35) using colloidal human serum albumin, and by 
Moore et al.  (36) using bovine serum albumin. With ssDNA, there was no lag 
phase, and there was a significant increase in soluble label by 2 rain, reaching 
a  peak at 30  rain,  the time at which breakdown products from a  phagocytic 
process are just beginning to appear (Fig. 5). This strongly suggested that the 
exonuclease was not intracellular and did not depend upon prior phagocytosis, 
but was either a circulating or a membrane-bound enzyme. However, as shown 
in Table I, we were unable to show any significant plasma exonuclease activity. 
Since a  number of studies (37, 38) have reported masking to serum nuclease 
activity by  inhibitors released from cells  during clotting,  we  used  carefully 
prepared  fresh  plasma  without anticoagulants.  We  also  checked for plasma 
exonuclease inhibitors by adding plasma to  a  commercial enzyme of known 
activity. We were unable to show inhibitors which might have been masking 
exonuclease activity. This  suggested that the  exonuclease system may be  a 
membrane-bound  enzyme.  Since  such  a  large  amount of the  injected  DNA 
went to  the  liver,  this  is  potentially the  location of this  enzyme. It  is  well 
known (39-41)  that the liver is rich in nucleases and that 5'  nucleotidase, an 
exonuclease, is a liver membrane-bound glycoprotein (39). 
If liver uptake in our system were simply a  matter of binding of substrate 
(precipitable ssDNA) to enzyme with release of product (soluble mononucleo- 
tide),  one  would  expect  a  close  relationship  between  saturability curves  of 
DNA clearance, liver uptake, and soluble product released. As discussed above, 
this  was true  of the  DNA  clearance  and liver uptake curves.  However, the 
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130-~g/ml K m and a 0.2-~g/ml/minute Vm. The difference between this V~ and 
the  V~  for  liver  uptake  can  be  explained  on  the  basis  of the  rapid  renal 
excretion of breakdown products, but the large difference between the two Km 
is hard to explain. A renal threshold, enabling soluble products at high doses 
to persist in circulation, or cellular reuptake of nucleotides, which in itself is 
saturable, could both account for the increased Kin. However, we do not have 
enough data at this time to explain this value. Although we are confident that 
the  exonuclease activity resides  in  the  liver  and is  probably  not  dependent 
upon  phagocytosis,  we  cannot  conclude  that  ssDNA  binds  directly  to  this 
enzyme with subsequent release of mononucleotides. 
Previous work  has  demonstrated that  DNA  is  a  good inducer of in  vitro 
pinocytosis  in  macrophages  (42). Furthermore,  when  daunorubicin,  a  drug 
which  alone  readily  diffuses  into  tumor  cells,  was  complexed  with  DNA, 
daunorubicin entry into cells was slowed,  and it localized in lysosomes (43). 
This indirect evidence for the in vitro phagocytosis of DNA forms the basis for 
its use in the design of lysosomotropic drugs,  as proposed by de  Duve et al. 
(44). We could not find data, however, on the in vivo phagocytosis of DNA or 
on the in vivo breakdown of DNA in lysosomes. The absence of a  lag phase in 
the appearance of soluble DNA breakdown products in the circulation appears 
inconsistent with the concept of phagocytosis and intralysosomal breakdown of 
ssDNA.  Direct evidence on the cellular site of DNA breakdown is currently 
being sought. 
Endonuclease activity was measured in our model by the decrease in size of 
the  precipitable  ssDNA,  as  measured by polyacrylamide gel  electrophoresis 
(PAGE). Chused et al. (18), using sucrose density gradients, showed a decrease 
in size of DNA at 30 min.  We have shown (Fig. 6),  using the more sensitive 
PAGE  system,  that  precipitable  DNA  was  rapidly cleaved,  with  a  marked 
reduction in size at 1 min (Table II).  Since there was an absolute increase in 
the amount of smaller fragments, this could not be accounted for by selective 
removal of large ssDNA. Furthermore, in preliminary studies we demonstrated 
some of this activity in plasma in vitro. Although we certainly cannot rule out 
a  role  of tissue  endonucleases  as  well,  some  of the  endonuclease  activity 
appeared to reside in a  circulating enzyme. We do not yet have data on the 
saturability of this  enzyme, nor on  the  size  of its  final breakdown product. 
More homogenous DNA preparations will be necessary to answer these ques- 
tions. However, in our in vivo studies, many of the polynucleotide fragments 
were 100 nucleotides or less, corresponding to a  mol wt of ---20,000-30,000. The 
antigenicity and  immunogenicity of polynucleotides this  size  are  not  well 
defined,  and  will  require  further  investigation.  However,  these  fragments 
could potentially pass through the glomerular basement membrane and lodge 
in the subepithelial area to combine locally with antibodies. It is of interest 
that the binding of ssDNA  to  glomerular basement membrane preparations 
and the local formation of immune complexes with antibodies to DNA has been 
demonstrated in vitro by Izui et al.  (45). 
In  conclusion,  we  have  presented  evidence  which  suggests  that  injected 
ssDNA is rapidly removed and degraded in vivo by two enzyme systems acting 
simultaneously. Large molecular weight ssDNA is cleaved into smaller frag- WOODRUFF  EMLEN  AND  MART  MANNIK  697 
ments by a circulating endonuclease. These fragments (as well as the original 
DNA) are bound to the liver where they are attacked by what appears to be a 
membrane-associated  exonuclease  which  cleaves  off mononucleotides.  This 
exonuclease  system  is  saturable,  so  that  with  increasing  doses  of ssDNA 
administered, more pelynucleotide fragments persist in the circulation and are 
available for attack by endonucleases. The fate of these persistent pelynucleo- 
tide fragments and their potential role in formation of immune complexes, in 
induction of an immune response,  or in local deposition in tissues is not yet 
clear.  However, the behavior of these fragments, as well as the existence of 
factors which might alter DNA clearance and lead to their persistence, seem 
pertinent to our understanding of human and murine SLE. 
Summary 
Clearance  of exogenous  ssDNA  from  circulation  was  rapid  and  occurred 
primarily  through  the  liver.  With  higher  doses  of  single-stranded  DNA 
(ssDNA), both liver uptake and whole blood clearance approached a maximum, 
enabling  larger  amounts of ssDNA  to  persist  in  the  circulation.  The  large 
molecular weight material (precipitable ssDNA) which remained in circulation 
was rapidly cleaved to 20,000-30,000  mol wt fragments by endonucleases, at 
least some of which could be demonstrated in plasma in vitro. Mononucleotide 
breakdown products appeared rapidly in circulation with no lag phase, suggest- 
ing that exonuclease activity was not dependent upon prior phagocytosis. Since 
no  exonuclease  activity  could  be  demonstrated  in  plasma  in  vitro,  it  was 
postulated that breakdown of ssDNA by exonucleases occurs on the surface of 
hepatocytes or Kupffer cells. 
We wish to  thank Ms. Trish Fadling for  her  excellent  technical  assistance. 
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